Important note: Information in this article was accurate in September 2006. The state of the art may have changed since the publication date.
French study raises importance of early screening for anal cancer in HIV-positive people
HIV Treat Bull - Vol. 7, No. 7/8, September 2006
Christophe Piketty and colleagues looked at the impact of HAART on incidence of anal cancer diagnosed between 1992 and 2003 in HIV-positive patients from the French Database of HIV (FHDH). The analysis looked at pre-HAART, early HAART, and later HAART time periods. 92 cases were identified (84 men, 8 women) from almost 75,000 patients in the database.
Among men, 74% were men who have sex with men. The median age at diagnosis was 42.4 years [IQR: 36.0-49.3]; the median CD4 cell count was 247 cells/mm3 [IQR: 135-420]; the median nadir CD4 cell count was 80 cells/mm3 [IQR: 21-174] and 39% of the cases had presented an AIDS defining event prior to the anal cancer diagnosis. At diagnosis, 71 patients (77%) had been receiving HAART for over five years (median 65 months [IQR: 44-77]).
Table 1: Changes in incidence rate of anal cancer
The incidence of anal cancer increased, in both the whole HIV-cohort, and in HIV-positive men who have sex with men (MSM), though the risk in MSM was approximately twice as high, and is detailed in Table 1. The increase in all rates was explained by the investigators by longer life expectancy conferred by HAART, in that people are living long enough for malignancies to develop. The survival probability after the anal cancer diagnosis was 74%+/-6% at 3 years.
The conclusion drawn by the researchers was that as HAART exhibited no favorable effect on the incidence of anal cancer, this ‘supported the urgent need for developing anal cancer screening programs for HIV-infected individuals’.
Reference
1. Piketty C, Selinger-Leneman H, Grabar S et al. Dramatic increase in the incidence of anal cancer despite HAART in the French hospital database of HIV. XVI International AIDS Conference, Toronto, Canada. 13 - 18 August 2006. Oral abstract TUAB0305.
2006-09-10
IB060709-20
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.